ReShape Lifesciences Return on Equity

ReShape Lifesciences (RSLS) currently reports a ROE of -161.66%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore ReShape Lifesciences's ROE history and peer comparisons.

ReShape Lifesciences's ROE of -161.66% is lower than the Healthcare sector average of 21.67%. That is roughly 846.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ReShape Lifesciences's current -161.66% should be judged against Healthcare norms (sector average: 21.67%) and against RSLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -161.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for ReShape Lifesciences, and consider following RSLS for alerts when major investors trade the stock.

ReShape Lifesciences is classified in the Healthcare sector. On ROE, it currently shows -161.66% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RSLS with unrelated industries.